These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9707678)

  • 1. The effect of triclabendazole (Fasinex) in children with fasciolosis.
    Yilmaz H; Oner AF; Akdeniz H; Arslan S
    J Egypt Soc Parasitol; 1998 Aug; 28(2):497-502. PubMed ID: 9707678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica.
    Keiser J; Utzinger J; Vennerstrom JL; Dong Y; Brennan G; Fairweather I
    Trans R Soc Trop Med Hyg; 2007 Dec; 101(12):1219-22. PubMed ID: 17905370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fasinex (triclabendazole)--a new fasciolicide].
    Eckert J; Schneiter G; Wolff K
    Berl Munch Tierarztl Wochenschr; 1984 Oct; 97(10):349-56. PubMed ID: 6517845
    [No Abstract]   [Full Text] [Related]  

  • 4. Compartive studies on the effect of bithionol, praziqantel and triclabendazole in rabbit's fascioliasis. 1. Parasitological studies.
    el-Sayad MH
    J Egypt Soc Parasitol; 1997 Apr; 27(1):131-42. PubMed ID: 9097534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fasciola hepatica infection. Successful therapy using triclabendazole].
    Markwalder K; Koller M; Goebel N; Wolff K
    Schweiz Med Wochenschr; 1988 Jul; 118(27-28):1048-52. PubMed ID: 3413464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infection with Fasciola hepatica.
    Aksoy DY; Kerimoglu U; Oto A; Erguven S; Arslan S; Unal S; Batman F; Bayraktar Y
    Clin Microbiol Infect; 2005 Nov; 11(11):859-61. PubMed ID: 16216098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgM and IgG cystatin capture enzyme linked immunosorbent assays: a tool for serodiagnosis and assessment of cure of acute fascioliasis after triclabendazole (TCZ; Fasinex) therapy.
    Tawfeek GM; Hussein DA
    J Egypt Soc Parasitol; 2000 Dec; 30(3):679-97. PubMed ID: 11198366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures.
    Marcos L; Maco V; Terashima A
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):817-823. PubMed ID: 33267701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triclabendazole in the treatment of human fascioliasis: a review.
    Gandhi P; Schmitt EK; Chen CW; Samantray S; Venishetty VK; Hughes D
    Trans R Soc Trop Med Hyg; 2019 Dec; 113(12):797-804. PubMed ID: 31638149
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Park HJ; Choi GS; Jung M; Lee SU
    Korean J Gastroenterol; 2021 Jan; 77(1):39-44. PubMed ID: 33495431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison between albendazole and triclabendazole against Fasciola gigantica in human].
    Fang W; Chen F; Liu HK; Yang Q; Yang L
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2014 Feb; 26(1):106-8. PubMed ID: 24800585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.
    Talaie H; Emami H; Yadegarinia D; Nava-Ocampo AA; Massoud J; Azmoudeh M; Mas-Coma S
    Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):777-82. PubMed ID: 15566392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human fascioliasis.
    Saba R; Korkmaz M; Inan D; Mamikoğlu L; Turhan O; Günseren F; Cevikol C; Kabaalioğlu A
    Clin Microbiol Infect; 2004 May; 10(5):385-7. PubMed ID: 15113313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemorrhagic ascites disclosing massive Fasciola hepatica infection].
    Montembault S; Serfaty L; Poirot JL; Wendum D; Penna C; Poupon R
    Gastroenterol Clin Biol; 1997; 21(10):785-8. PubMed ID: 9587520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of triclabendazole against Fasciola hepatica and Fascioloides magna in naturally infected calves.
    Craig TM; Huey RL
    Am J Vet Res; 1984 Aug; 45(8):1644-5. PubMed ID: 6476577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human fascioliasis in Egyptian children: successful treatment with triclabendazole.
    el-Karaksy H; Hassanein B; Okasha S; Behairy B; Gadallah I
    J Trop Pediatr; 1999 Jun; 45(3):135-8. PubMed ID: 10401189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass Drug Administration of Triclabendazole for
    Mollinedo S; Gutierrez P; Azurduy R; Valle F; Salas A; Mollinedo Z; Soto P; Villarroel CF; Ransom J; Lawrence R; Berman J; Soto J
    Am J Trop Med Hyg; 2019 Jun; 100(6):1494-1497. PubMed ID: 31115295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of human fascioliasis in Van province, Turkey.
    Taş Cengiz Z; Yılmaz H; Dülger AC; Akdeniz H; Karahocagil MK; Çiçek M
    Turk J Gastroenterol; 2015 May; 26(3):259-62. PubMed ID: 26006203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant capacity in Fasciola hepatica patients before and after treatment with triclabendazole alone or in combination with ascorbic acid (vitamin C) and tocofersolan (vitamin E).
    Rehim WM; Sharaf IA; Hishmat M; el-Toukhy MA; Rawash NA; Fouad HN
    Arzneimittelforschung; 2003; 53(3):214-20. PubMed ID: 12705178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Fascioliasis in The Metropolitan Area of Curitiba, Brazil Evaluation of The Foci of Infection and Report of Nine Cases Treated With Triclabendazole.
    Luz JE; Focaccia Siciliano R ; de Oliveira AG; Pisani JC
    Braz J Infect Dis; 1999 Dec; 3(6):220-225. PubMed ID: 11084672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.